Evidence map›Paper›PMID 30877308›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2020

Maternal Vaccination in Argentina: Tetanus, Diphtheria, and Acellular Pertussis Vaccine Effectiveness During Pregnancy in Preventing Pertussis in Infants <2 Months of Age.

Viviana Romanin, Anna M Acosta, Maria Del Valle Juarez, Elizabeth Briere, Stella Maris Sanchez, Beatriz Lopez Cordoba, Maria Eugenia Sevilla, Maria Florencia Lucion, Anahi Urrutia, Sandra Sagradini and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 2 pooled it
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 47 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Improving Tdap maternal immunization rate in Saudi Arabia.Human vaccines & immunotherapeutics · 2023
    Article
  12. Article
  13. Article
  14. Review
  15. Effect of pertussis vaccine in pregnancy and COVID-19 pandemic in the cases of wooping cough.Enfermedades infecciosas y microbiologia clinica (English ed.) · 2022
    Article
  16. Article
  17. Maternal RSV vaccine development. Where to from here?Human vaccines & immunotherapeutics · 2021
    Article
  18. Impact of Extending the Timing of Maternal Pertussis Vaccination on Hospitalized Infant Pertussis in England, 2014-2018.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 4 countries.

Viviana RomaninDirección de Control de Enfermedades Inmunoprevenibles, Ministerio de Salud de la Nación, Buenos Aires, Argentina.
Anna M AcostaMeningitis and Vaccine Preventable Diseases Branch, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.
Maria Del Valle JuarezDirección de Control de Enfermedades Inmunoprevenibles, Ministerio de Salud de la Nación, Buenos Aires, Argentina.
Elizabeth BriereMeningitis and Vaccine Preventable Diseases Branch, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.
Stella Maris SanchezHospital del Niño Jesús, Tucumán, Salta.
Beatriz Lopez CordobaHospital Público Materno Infantil, Salta.
Maria Eugenia SevillaHospital "P. de Elizalde, Argentina.
Maria Florencia LucionHospital de Niños "R. Gutiérrez," Buenos Aires, Argentina.
Anahi UrrutiaHospital "Dr. H. Heller," Neuquén, Argentina.
Sandra SagradiniDirección de Control de Enfermedades Inmunoprevenibles, Ministerio de Salud de la Nación, Buenos Aires, Argentina.
Tami H SkoffMeningitis and Vaccine Preventable Diseases Branch, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.
Carla VizzottiDirección de Control de Enfermedades Inmunoprevenibles, Ministerio de Salud de la Nación, Buenos Aires, Argentina.
Ministerio de Salud · ARNational Center for Immunization and Respiratory Diseases · USHospital del Niño · PAHospital General de Niños Ricardo Gutierrez · ARHospital Materno-Infantil · ESHospital Pedro de Elizalde · AR

Funding

Intramural CDC HHS CC999999
6 · The paper itself

Abstract

backgroundIn 2011, Argentina experienced its highest pertussis incidence and mortality rates of the last decade; 60% of deaths were among infants aged <2 months. In response, a dose of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine was recommended for all pregnant women at ≥20 weeks of gestation. Although recent studies suggest that maternal Tdap vaccination is effective at preventing infant disease, no data have come from low- or middle-income countries, nor from ones using whole-cell pertussis vaccines for primary immunization.

methodsWe conducted a matched case-control evaluation to assess the effectiveness of maternal Tdap vaccination in preventing pertussis among infants aged <2 months in Argentina. Pertussis case patients identified from September 2012 to March 2016 at 6 hospital sites and confirmed by polymerase chain reaction testing were included. Five randomly selected controls were matched to each case patient by hospital site and mother's health district. We used multivariable conditional logistic regression to calculate odds ratios (ORs). Vaccine effectiveness (VE) was estimated as (1 - OR) × 100%.

resultsSeventy-one case patients and 300 controls were included in the analysis. Forty-nine percent of case patients and 78% of controls had mothers who were vaccinated during pregnancy. Overall Tdap VE was estimated at 80.7% (95% confidence interval, 52.1%-92.2%). We found similar VE whether Tdap was administered during the second or third trimester.

conclusionsTdap vaccination during pregnancy is effective in preventing pertussis in infants aged <2 months in Argentina, with similar effectiveness whether administered during the second or third trimester of pregnancy.

Indexed as

DiphtheriaDiphtheria-Tetanus-acellular Pertussis VaccinesTetanusWhooping CoughArgentinaFemaleHumansInfantPregnancyVaccinationDiphtheria-Tetanus-acellular Pertussis Vaccinesinfant pertussismaternal immunizationpregnancyTdapvaccine effectiveness

Identifiers

PMID30877308
PMCPMC8876368
OpenAlexW2920994403

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.